Step Pharma, the global leader in CTPS1 inhibition for targeted cancer treatment, today announced that its lead asset dencatistat (STP938), a first-in-class selective CTPS1 inhibitor, has cleared an investigational new drug (IND) application by the US Food and Drug Administration (FDA), enabling Step Pharma to progress dencatistat into a Phase 1 clinical trial for patients with solid tumours, anticipated to start in Q3 2024.
The project was supported by MATWIN and awarded ‘First-in-class therapeutic innovation’ by MATWIN Board in 2021 !
Press release : https://step-ph.com/step-pharma-announces-us-fda-clearance-for-a-phase-i-clinical-trial-in-solid-tumours-with-dencatistat-stp938/
